{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:34:26Z","timestamp":1781811266104,"version":"3.54.5"},"reference-count":186,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.idc.2021.03.005","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T01:23:18Z","timestamp":1621300998000},"page":"341-371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Antifungals in Clinical Use and the Pipeline"],"prefix":"10.1016","volume":"35","author":[{"given":"Melissa D.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.idc.2021.03.005_bib1","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.cmi.2019.05.019","article-title":"ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children","volume":"25","author":"Warris","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 7","key":"10.1016\/j.idc.2021.03.005_bib2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1469-0691.12040","article-title":"ESCMID\u2217 guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp","volume":"18","author":"Hope","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idc.2021.03.005_bib3","first-page":"377","article-title":"Aqueous pores created in thin lipid membranes by the polyene antibiotics nystatin and amphotericin B","volume":"2","author":"Finkelstein","year":"1973","journal-title":"Membranes"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.idc.2015.10.012","article-title":"Antifungal agents: spectrum of activity, pharmacology, and clinical indications","volume":"30","author":"Nett","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.idc.2021.03.005_bib5","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.3389\/fmicb.2019.02788","article-title":"Review on antifungal resistance mechanisms in the emerging pathogen Candida auris","volume":"10","author":"Chaabane","year":"2019","journal-title":"Front Microbiol"},{"issue":"11","key":"10.1016\/j.idc.2021.03.005_bib6","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1348-0421.1999.tb01231.x","article-title":"Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus","volume":"43","author":"Seo","year":"1999","journal-title":"Microbiol Immunol"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib7","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1128\/AAC.41.1.196","article-title":"Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia","volume":"41","author":"Nolte","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/cid\/ciy411","article-title":"Molecular Epidemiology of Candida auris in colombia reveals a highly related, countrywide colonization with regional patterns in amphotericin B resistance","volume":"68","author":"Escand\u00f3n","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/pharmaceutics12010029","article-title":"Lipid systems for the delivery of amphotericin b in antifungal therapy","volume":"12","author":"Faustino","year":"2020","journal-title":"Pharmaceutics"},{"issue":"Supplement_1","key":"10.1016\/j.idc.2021.03.005_bib10","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1086\/504492","article-title":"Pharmacology of systemic antifungal agents","volume":"43","author":"Ashley","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2021.03.005_bib11","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1128\/AAC.02535-14","article-title":"In\u00a0vitro and in\u00a0vivo evidence for amphotericin B as a P-glycoprotein substrate on the blood-brain barrier","volume":"58","author":"Wu","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2021.03.005_bib12","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2021.03.005_bib13","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1128\/AAC.04768-14","article-title":"The brain, amphotericin B, and P-glycoprotein","volume":"59","author":"Stevens","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2021.03.005_bib14","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1128\/AAC.04723-14","article-title":"Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus","volume":"59","author":"Al-Nakeeb","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.idc.2021.03.005_bib15","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1128\/AAC.44.10.2900-2902.2000","article-title":"A\u00a0pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections","volume":"44","author":"Adedoyin","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.idc.2021.03.005_bib16","doi-asserted-by":"crossref","first-page":"e00838","DOI":"10.1128\/AAC.00838-20","article-title":"Phase I EnACT trial of the safety and tolerability of a novel oral formulation of amphotericin B","volume":"64","author":"Skipper","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2021.03.005_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions","volume":"46","author":"Vermes","year":"2000","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue penetration of antifungal agents","volume":"27","author":"Felton","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.idc.2021.03.005_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13054-015-0758-3","article-title":"Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study","volume":"19","author":"Sinnollareddy","year":"2015","journal-title":"Crit Care"},{"issue":"7","key":"10.1016\/j.idc.2021.03.005_bib20","doi-asserted-by":"crossref","first-page":"e00585","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/cpdd.280","article-title":"Pharmacokinetic interactions between isavuconazole and the drug transporter substrates atorvastatin, digoxin, metformin, and methotrexate in healthy subjects","volume":"6","author":"Yamazaki","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9","key":"10.1016\/j.idc.2021.03.005_bib22","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2021.03.005_bib23","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1517\/17425255.2013.794785","article-title":"Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections","volume":"9","author":"Lestner","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"10.1016\/j.idc.2021.03.005_bib24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/jac\/8.4.299","article-title":"Pharmacokinetics of ketoconazole in normal subjects","volume":"8","author":"Daneshmend","year":"1981","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.idc.2021.03.005_bib25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/j.1875-9114.1984.tb03398.x","article-title":"Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use","volume":"4","author":"Van Tyle","year":"1984","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.idc.2021.03.005_bib26","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1128\/AAC.00769-08","article-title":"Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir","volume":"53","author":"Kaeser","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2021.03.005_bib27","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40265-020-01306-y","article-title":"Pharmacokinetics and Pharmacodynamics of Posaconazole","volume":"80","author":"Chen","year":"2020","journal-title":"Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.03.005_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1365-2125.2003.01998.x","article-title":"Voriconazole does not affect the steady-state pharmacokinetics of digoxin","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.idc.2021.03.005_bib29","doi-asserted-by":"crossref","first-page":"624.e1","DOI":"10.1016\/j.ajog.2018.03.001","article-title":"A\u00a0phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis","volume":"218","author":"Brand","year":"2018","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.idc.2021.03.005_bib30","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1128\/AAC.03707-14","article-title":"The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme","volume":"58","author":"Warrilow","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2021.03.005_bib31","doi-asserted-by":"crossref","first-page":"e00111","DOI":"10.1128\/AAC.00111-17","article-title":"Efficacy of the Investigational Antifungal VT-1161 in Treating Naturally Occurring Coccidioidomycosis in Dogs","volume":"61","author":"Shubitz","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2021.03.005_bib32","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1128\/AAC.00185-15","article-title":"Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis","volume":"59","author":"Garvey","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2021.03.005_bib33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/2047-783X-16-4-159","article-title":"Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature","volume":"16","author":"Kofla","year":"2011","journal-title":"Eur J Med Res"},{"issue":"3","key":"10.1016\/j.idc.2021.03.005_bib34","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1128\/AAC.48.3.815-823.2004","article-title":"Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma","volume":"48","author":"Stone","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2021.03.005_bib35","doi-asserted-by":"crossref","first-page":"e01627","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2021.03.005_bib36","article-title":"Rezafungin versus Caspofungin in a Phase 2, randomized, double-blind study for the treatment of Candidemia and Invasive Candidiasis- The STRIVE Trial","author":"Thompson","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2021.03.005_bib37","doi-asserted-by":"crossref","first-page":"e01626","DOI":"10.1128\/AAC.01626-16","article-title":"Pharmacokinetics of the novel echinocandin CD101 in multiple animal species","volume":"61","author":"Ong","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.03.005_bib38","doi-asserted-by":"crossref","first-page":"S658","DOI":"10.1093\/ofid\/ofaa439.1469","article-title":"1286. Pharmacokinetics, excretion, and mass balance of [14C]-Rezafungin Following Intravenous (IV) Administration in Healthy Adults","volume":"7","author":"Ong","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2021.03.005_bib39","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/13543784.2020.1791820","article-title":"Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis","volume":"29","author":"Azie","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"10.1016\/j.idc.2021.03.005_bib40","doi-asserted-by":"crossref","first-page":"e02068","DOI":"10.1128\/AAC.02068-16","article-title":"Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis","volume":"61","author":"Wring","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib41","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cpdd.588","article-title":"clinical pharmacokinetics and drug-drug interaction potential for Coadministered SCY-078, an oral fungicidal glucan synthase inhibitor, and tacrolimus","volume":"8","author":"Wring","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"10.1016\/j.idc.2021.03.005_bib42","first-page":"122","article-title":"Review of the novel investigational antifungal Olorofim","volume":"6","author":"Wiederhold","year":"2020","journal-title":"J\u00a0Fungi (Basel)"},{"key":"10.1016\/j.idc.2021.03.005_bib43","series-title":"Proceedings of the 27th European congress of clinical microbiology and infectious Diseases","article-title":"Multiple dose pharmacokinetics of an immediate-release tablet formulation of F901318 in healthy male and female subjects","author":"Kennedy","year":"2017"},{"issue":"4","key":"10.1016\/j.idc.2021.03.005_bib44","first-page":"239","article-title":"Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections","volume":"6","author":"Shaw","year":"2020","journal-title":"J\u00a0Fungi (Basel)"},{"key":"10.1016\/j.idc.2021.03.005_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02372-18","article-title":"APX001 Pharmacokinetic\/Pharmacodynamic target determination against aspergillus fumigatus in an in\u00a0vivo model of invasive pulmonary aspergillosis","author":"Zhao","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.03.005_bib46","doi-asserted-by":"crossref","first-page":"S534","DOI":"10.1093\/ofid\/ofx163.1390","article-title":"Phase 1 study to assess safety, tolerability and pharmacokinetics of single and multiple oral doses of APX001 and to investigate the effect of food on APX001 bioavailability","volume":"4","author":"Hodges","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2021.03.005_bib47","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation","volume":"26","author":"G\u00f3mez-L\u00f3pez","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.idc.2021.03.005_bib48","doi-asserted-by":"crossref","first-page":"a019653","DOI":"10.1101\/cshperspect.a019653","article-title":"Antifungal pharmacokinetics and pharmacodynamics","volume":"5","author":"Lepak","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"10.1016\/j.idc.2021.03.005_bib49","doi-asserted-by":"crossref","first-page":"e01157","DOI":"10.1128\/mBio.01157-17","article-title":"Pharmacodynamics of the orotomides against aspergillus fumigatus: new opportunities for treatment of multidrug-resistant fungal disease","volume":"8","author":"Hope","year":"2017","journal-title":"MBio"},{"key":"10.1016\/j.idc.2021.03.005_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/1178636119869937","article-title":"Inhaled Amphotericin B as aspergillosis prophylaxis in hematologic disease: an update","volume":"12","author":"Duckwall","year":"2019","journal-title":"Microbiol Insights"},{"issue":"2","key":"10.1016\/j.idc.2021.03.005_bib51","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11046-019-00331-0","article-title":"aerosolized lipid amphotericin B for complementary therapy and\/or secondary prophylaxis in patients with invasive pulmonary aspergillosis: a single-center experience","volume":"184","author":"Venanzi","year":"2019","journal-title":"Mycopathologia"},{"issue":"10","key":"10.1016\/j.idc.2021.03.005_bib52","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/phar.1309","article-title":"Aerosolized amphotericin B lipid complex as adjunctive treatment for fungal lung infection in patients with cancer-related immunosuppression and recipients of hematopoietic stem cell transplantation","volume":"33","author":"Safdar","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.idc.2021.03.005_bib53","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1592\/phco.28.5.614","article-title":"Current options in antifungal pharmacotherapy","volume":"28","author":"Mohr","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.idc.2021.03.005_bib54","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: a comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.idc.2021.03.005_bib55","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/jac\/dkt055","article-title":"An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity","volume":"68","author":"Chai","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.idc.2021.03.005_bib56","article-title":"Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function","author":"Botero Aguirre","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.idc.2021.03.005_bib57","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/myc.12585","article-title":"Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis","volume":"60","author":"Steimbach","year":"2017","journal-title":"Mycoses"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.03.005_bib58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/49.suppl_1.7","article-title":"Amphotericin B: spectrum and resistance","volume":"49","author":"Ellis","year":"2002","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.idc.2021.03.005_bib59","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/376634","article-title":"Amphotericin B: time for a new \u201cGold Standard\u201d","volume":"37","author":"Saravolatz","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.idc.2021.03.005_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/1469-0691.12465","article-title":"ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others","volume":"20","author":"Tortorano","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.03.005_bib61","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.idc.2021.03.005_bib62","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/pharmaceutics11030099","article-title":"The development of oral amphotericin b to treat systemic fungal and parasitic infections: has the myth been finally realized?","volume":"11","author":"Cuddihy","year":"2019","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.idc.2021.03.005_bib63","first-page":"66","article-title":"Encochleated Amphotericin B: Is the oral availability of amphotericin b finally reached?","volume":"6","author":"Aigner","year":"2020","journal-title":"J\u00a0Fungi (Basel)"},{"issue":"6","key":"10.1016\/j.idc.2021.03.005_bib64","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1128\/AAC.44.6.1463-1469.2000","article-title":"Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model","volume":"44","author":"Zarif","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2021.03.005_bib65","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/jps.10173","article-title":"Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system","volume":"91","author":"Segarra","year":"2002","journal-title":"J\u00a0Pharm Sci"},{"issue":"3","key":"10.1016\/j.idc.2021.03.005_bib66","doi-asserted-by":"crossref","first-page":"e00724","DOI":"10.1128\/mBio.00724-19","article-title":"Efficacy of oral encochleated amphotericin b in a mouse model of cryptococcal meningoencephalitis","volume":"10","author":"Lu","year":"2019","journal-title":"MBio"},{"issue":"2","key":"10.1016\/j.idc.2021.03.005_bib68","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000238485","article-title":"In\u00a0vitro and in\u00a0vivo drug studies with three agents of central nervous system phaeohyphomycosis","volume":"33","author":"Dixon","year":"1987","journal-title":"Chemotherapy"},{"issue":"11","key":"10.1016\/j.idc.2021.03.005_bib69","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1128\/AAC.46.11.3518-3521.2002","article-title":"In\u00a0vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods","volume":"46","author":"Pfaller","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2021.03.005_bib70","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0002-9343(87)90691-7","article-title":"Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis","volume":"83","author":"Stamm","year":"1987","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.idc.2021.03.005_bib71","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2021.03.005_bib72","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib73","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1128\/CMR.00032-16","article-title":"Chromoblastomycosis","volume":"30","author":"Queiroz-Telles","year":"2017","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl 3","key":"10.1016\/j.idc.2021.03.005_bib74","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/1469-0691.12515","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi","volume":"20","author":"Chowdhary","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.idc.2021.03.005_bib75","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1128\/AAC.00905-16","article-title":"Aspergillus fumigatus intrinsic fluconazole resistance is due to the naturally occurring T301I substitution in Cyp51Ap","volume":"60","author":"Leonardelli","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2021.03.005_bib76","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2217\/fmb-2018-0059","article-title":"Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside","volume":"13","author":"Beardsley","year":"2018","journal-title":"Future Microbiol"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.03.005_bib77","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","article-title":"Twenty years of the sentry antifungal surveillance program: results for Candida species from 1997-2016","volume":"6","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2021.03.005_bib78","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1128\/AEM.00231-09","article-title":"Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles","volume":"75","author":"Snelders","year":"2009","journal-title":"Appl Environ Microbiol"},{"issue":"4","key":"10.1016\/j.idc.2021.03.005_bib79","doi-asserted-by":"crossref","first-page":"e01651","DOI":"10.1128\/AAC.01651-19","article-title":"Mechanisms of acquired in\u00a0vivo and in\u00a0vitro resistance to voriconazole by Candida Krusei following exposure to suboptimal drug concentration","volume":"64","author":"Ricardo","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib80","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/AAC.03470-14","article-title":"Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans","volume":"59","author":"Flowers","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2021.03.005_bib81","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1093\/jac\/dkz258","article-title":"Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients","volume":"74","author":"Resendiz-Sharpe","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.idc.2021.03.005_bib82","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/cid\/ciy859","article-title":"Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study","volume":"68","author":"Lestrade","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib83","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2021.03.005_bib84","first-page":"90","article-title":"Isavuconazole treatment in a mixed patient cohort with invasive fungal infections: outcome, tolerability and clinical implications of Isavuconazole plasma concentrations","volume":"6","author":"Zurl","year":"2020","journal-title":"J\u00a0Fungi (Basel)"},{"issue":"10","key":"10.1016\/j.idc.2021.03.005_bib85","doi-asserted-by":"crossref","first-page":"e02474","DOI":"10.1128\/AAC.02474-18","article-title":"Isavuconazole diffusion in infected human brain","volume":"63","author":"Rouzaud","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib86","doi-asserted-by":"crossref","first-page":"e01511","DOI":"10.1128\/AAC.01511-20","article-title":"Isavuconazole therapeutic drug monitoring during long-term treatment for chronic pulmonary aspergillosis","volume":"65","author":"Kosmidis","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2021.03.005_bib87","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1128\/AAC.00973-15","article-title":"Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states","volume":"59","author":"Abuhelwa","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2021.03.005_bib88","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/cpt.809","article-title":"Impact of CYP3A4 genotype on voriconazole exposure","volume":"103","author":"Duflot","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib89","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.idc.2021.03.005_bib90","series-title":"Vfend (voriconazole) [package insert]","year":"2019"},{"issue":"7","key":"10.1016\/j.idc.2021.03.005_bib91","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/phar.1400","article-title":"CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?","volume":"34","author":"Owusu Obeng","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.idc.2021.03.005_bib92","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/jac\/dkp026","article-title":"Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation","volume":"63","author":"Spriet","year":"2009","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib93","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/phar.1156","article-title":"Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review","volume":"33","author":"Davies-Vorbrodt","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1016\/j.idc.2021.03.005_bib94","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1093\/jac\/dks312","article-title":"Evaluation of the effect of obesity on voriconazole serum concentrations","volume":"67","author":"Koselke","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.idc.2021.03.005_bib95","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","article-title":"Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults","volume":"47","author":"Courtney","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2021.03.005_bib96","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2021.03.005_bib97","first-page":"1","article-title":"Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections","volume":"8","author":"Wiederhold","year":"2016","journal-title":"Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.idc.2021.03.005_bib98","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/phar.1652","article-title":"Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a New Triazole antifungal agent","volume":"35","author":"Rybak","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.idc.2021.03.005_bib99","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Br\u00fcggemann","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2021.03.005_bib100","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1128\/AAC.00054-16","article-title":"Drug-drug interaction associated with mold-active Triazoles among hospitalized patients","volume":"60","author":"Andes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2021.03.005_bib101","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00277-020-04107-1","article-title":"Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma","volume":"99","author":"Stemler","year":"2020","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.idc.2021.03.005_bib102","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/myc.12731","article-title":"Isavuconazole shortens the QTc interval","volume":"61","author":"Mellinghoff","year":"2018","journal-title":"Mycoses"},{"issue":"8","key":"10.1016\/j.idc.2021.03.005_bib103","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-019-01127-8","article-title":"Adverse effects associated with long-term administration of azole antifungal agents","volume":"79","author":"Benitez","year":"2019","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.idc.2021.03.005_bib104","doi-asserted-by":"crossref","first-page":"E179","DOI":"10.1503\/cmaj.180963","article-title":"Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies","volume":"191","author":"B\u00e9rard","year":"2019","journal-title":"CMAJ"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib105","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jama.2015.17844","article-title":"Association between use of oral fluconazole during pregnancy and risk of Spontaneous Abortion and Stillbirth","volume":"315","author":"M\u00f8lgaard-Nielsen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.idc.2021.03.005_bib106","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.reprotox.2020.12.018","article-title":"Maternal use of fluconazole and congenital malformations in the progeny: a meta-analysis of the literature","volume":"100","author":"Budani","year":"2020","journal-title":"Reprod Toxicol"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib107","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ijgo.12993","article-title":"Fetal outcomes after maternal exposure to oral antifungal agents during pregnancy: a systematic review and meta-analysis","volume":"148","author":"Liu","year":"2020","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"10.1016\/j.idc.2021.03.005_bib108","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2021.03.005_bib109","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.idc.2021.03.005_bib110","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaad.2018.08.010","article-title":"Voriconazole exposure and risk of cutaneous squamous cell carcinoma among lung or hematopoietic cell transplant patients: a systematic review and meta-analysis","volume":"80","author":"Tang","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.idc.2021.03.005_bib111","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/cid\/ciz741","article-title":"posaconazole serum drug levels associated with pseudohyperaldosteronism","volume":"70","author":"Nguyen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2021.03.005_bib112","doi-asserted-by":"crossref","first-page":"105605","DOI":"10.1016\/j.jsbmb.2020.105605","article-title":"Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals","volume":"199","author":"Beck","year":"2020","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"issue":"5","key":"10.1016\/j.idc.2021.03.005_bib113","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.mayocpiqo.2020.05.006","article-title":"The many faces of itraconazole cardiac toxicity","volume":"4","author":"Teaford","year":"2020","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"7","key":"10.1016\/j.idc.2021.03.005_bib114","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/jcph.84","article-title":"A\u00a0quantitative analysis of the spontaneous reporting of congestive heart failure-related adverse events with systemic anti-fungal drugs","volume":"53","author":"Hauben","year":"2013","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.idc.2021.03.005_bib115","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13054-015-0753-8","article-title":"Evaluation of sulfobutylether-\u03b2-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy","volume":"19","author":"Kiser","year":"2015","journal-title":"Crit Care"},{"issue":"10","key":"10.1016\/j.idc.2021.03.005_bib116","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/myc.12517","article-title":"Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether \u03b2-cyclodextrin in haematological patients with renal impairment","volume":"59","author":"Kim","year":"2016","journal-title":"Mycoses"},{"issue":"8","key":"10.1016\/j.idc.2021.03.005_bib117","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1002\/jps.22109","article-title":"Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD)","volume":"99","author":"Luke","year":"2010","journal-title":"J\u00a0Pharm Sci"},{"issue":"7","key":"10.1016\/j.idc.2021.03.005_bib118","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/cid\/cir969","article-title":"Administration of voriconazole in patients with renal dysfunction","volume":"54","author":"Neofytos","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2021.03.005_bib119","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ijantimicag.2015.05.023","article-title":"Worsening renal function in patients with baseline renal impairment treated with intravenous voriconazole: a systematic review","volume":"46","author":"Turner","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib120","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/0192623307310945","article-title":"Cyclodextrins","volume":"36","author":"Stella","year":"2008","journal-title":"Toxicol Pathol"},{"issue":"5","key":"10.1016\/j.idc.2021.03.005_bib121","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1592\/phco.19.8.603.31529","article-title":"Itraconazole in cyclodextrin solution","volume":"19","author":"Stevens","year":"1999","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.idc.2021.03.005_bib122","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1093\/jac\/dky270","article-title":"Trends in antifungal use in US hospitals, 2006\u201312","volume":"73","author":"Vallabhaneni","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.idc.2021.03.005_bib123","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1086\/588300","article-title":"Clinical practice guidelines for the management of blastomycosis: 2008 update by the infectious diseases society of America","volume":"46","author":"Chapman","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2021.03.005_bib124","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1093\/cid\/ciw360","article-title":"2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis","volume":"63","author":"Galgiani","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2021.03.005_bib125","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1086\/521259","article-title":"Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America","volume":"45","author":"Wheat","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2021.03.005_bib126","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1086\/522765","article-title":"Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America","volume":"45","author":"Kauffman","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2021.03.005_bib127","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2021.03.005_bib128","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2021.03.005_bib129","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.idc.2021.03.005_bib130","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.idc.2021.03.005_bib131","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1128\/AAC.00359-12","article-title":"Successful use of posaconazole for treatment of blastomycosis","volume":"56","author":"Proia","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2021.03.005_bib132","doi-asserted-by":"crossref","first-page":"e02232","DOI":"10.1128\/AAC.02232-18","article-title":"Isavuconazole in the treatment of coccidioidal meningitis","volume":"63","author":"Heidari","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"15","key":"10.1016\/j.idc.2021.03.005_bib133","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.bmcl.2017.06.037","article-title":"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors","volume":"27","author":"Yates","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"10.1016\/j.idc.2021.03.005_bib134","doi-asserted-by":"crossref","first-page":"e01817","DOI":"10.1128\/AAC.01817-16","article-title":"Fungal CYP51 inhibitors VT-1161 and VT-1129 exhibit strong in\u00a0vitro activity against Candida Glabrata and C. Krusei isolates clinically resistant to azole and echinocandin antifungal compounds","volume":"61","author":"Schell","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2021.03.005_bib135","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ijantimicag.2017.09.002","article-title":"The antifungal arsenal: alternative drugs and future targets","volume":"51","author":"Wiederhold","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.idc.2021.03.005_bib136","doi-asserted-by":"crossref","first-page":"e02233","DOI":"10.1128\/AAC.02233-18","article-title":"The fungal Cyp51-specific inhibitor VT-1598 demonstrates in\u00a0vitro and in\u00a0vivo activity against Candida auris","volume":"63","author":"Wiederhold","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2021.03.005_bib137","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/jac\/dkx410","article-title":"Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in\u00a0vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus","volume":"73","author":"Wiederhold","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.idc.2021.03.005_bib138","doi-asserted-by":"crossref","first-page":"e01315","DOI":"10.1128\/AAC.01315-18","article-title":"In\u00a0vivo efficacy of VT-1129 against experimental cryptococcal meningitis with the use of a loading dose-maintenance dose administration strategy","volume":"62","author":"Wiederhold","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2021.03.005_bib139","doi-asserted-by":"crossref","first-page":"e00833","DOI":"10.1128\/AAC.00833-17","article-title":"De novo acquisition of resistance to SCY-078 in Candida glabrata involves FKS mutations that both overlap and are distinct from those conferring echinocandin resistance","volume":"61","author":"Jim\u00e9nez-Ortigosa","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib140","first-page":"24","article-title":"Antifungal resistance among less prevalent candida non-albicans and other yeasts versus established and under development agents: a literature review","volume":"7","author":"Espinel-Ingroff","year":"2021","journal-title":"J\u00a0Fungi (Basel)"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib141","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/tcrm.2007.3.1.71","article-title":"Comparison of echinocandin antifungals","volume":"3","author":"Eschenauer","year":"2007","journal-title":"Ther Clin Risk Manag"},{"issue":"12","key":"10.1016\/j.idc.2021.03.005_bib142","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2021.03.005_bib143","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1128\/AAC.00027-12","article-title":"The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata","volume":"56","author":"Shields","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2021.03.005_bib144","doi-asserted-by":"crossref","first-page":"E343","DOI":"10.1111\/1469-0691.12212","article-title":"Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme","volume":"19","author":"Arendrup","year":"2013","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"10.1016\/j.idc.2021.03.005_bib145","doi-asserted-by":"crossref","first-page":"e02425","DOI":"10.1128\/AAC.02425-16","article-title":"Micafungin plasma levels are not affected by continuous renal replacement therapy: experience in critically Ill patients","volume":"61","author":"Vossen","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2021.03.005_bib146","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13054-018-2231-6","article-title":"Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies?","volume":"22","author":"Honore","year":"2018","journal-title":"Crit Care"},{"issue":"11","key":"10.1016\/j.idc.2021.03.005_bib147","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/INF.0000000000001268","article-title":"Pharmacokinetics and safety of micafungin in infants supported with extracorporeal membrane oxygenation","volume":"35","author":"Autmizguine","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"10.1016\/j.idc.2021.03.005_bib148","doi-asserted-by":"crossref","first-page":"e00687","DOI":"10.1128\/AAC.00687-20","article-title":"Population pharmacokinetics of caspofungin among extracorporeal membrane oxygenation patients during the postoperative period of lung transplantation","volume":"64","author":"Wang","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib149","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s13054-016-1501-4","article-title":"Pharmacokinetics of anidulafungin during venovenous extracorporeal membrane oxygenation","volume":"20","author":"Aguilar","year":"2016","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/j.idc.2021.03.005_bib150","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1051\/ject\/201749150","article-title":"Antifungal Extraction by the Extracorporeal Membrane Oxygenation Circuit","volume":"49","author":"Watt","year":"2017","journal-title":"J\u00a0Extra Corpor Technol"},{"issue":"4","key":"10.1016\/j.idc.2021.03.005_bib151","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/jac\/dky554","article-title":"Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults","volume":"74","author":"Wasmann","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.idc.2021.03.005_bib152","doi-asserted-by":"crossref","first-page":"e00063","DOI":"10.1128\/AAC.00063-18","article-title":"Pharmacokinetics of anidulafungin in obese and normal-weight adults","volume":"62","author":"Wasmann","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2021.03.005_bib153","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1128\/AAC.01490-12","article-title":"Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths","volume":"57","author":"Hall","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2021.03.005_bib154","doi-asserted-by":"crossref","first-page":"e00905","DOI":"10.1128\/AAC.00905-20","article-title":"Caspofungin weight-based dosing supported by a population pharmacokinetic model in critically Ill patients","volume":"64","author":"M\u00e4rtson","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2021.03.005_bib155","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/jac\/dky189","article-title":"Caspofungin dosage adjustments are not required for patients with Child-Pugh B or C cirrhosis","volume":"73","author":"Gustot","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.idc.2021.03.005_bib156","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"24","key":"10.1016\/j.idc.2021.03.005_bib157","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.idc.2021.03.005_bib158","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2021.03.005_bib159","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/DDDT.S3242","article-title":"Review of the pharmacology and clinical studies of micafungin","volume":"3","author":"Bormann","year":"2009","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.idc.2021.03.005_bib160","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jac\/dkz396","article-title":"Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals","volume":"75","author":"Schneeweiss","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.idc.2021.03.005_bib161","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1093\/jac\/dkw225","article-title":"Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study","volume":"71","author":"Schneeweiss","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.idc.2021.03.005_bib162","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"14","key":"10.1016\/j.idc.2021.03.005_bib163","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.idc.2021.03.005_bib164","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/cpdd.757","article-title":"Lack of effect of rezafungin on QT\/QTc interval in healthy subjects","volume":"9","author":"Flanagan","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"10.1016\/j.idc.2021.03.005_bib165","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/LGT.0000000000000473","article-title":"CD101 topical compared with oral fluconazole for acute vulvovaginal candidiasis: a randomized controlled trial","volume":"23","author":"Nyirjesy","year":"2019","journal-title":"J\u00a0Low Genit Tract Dis"},{"key":"10.1016\/j.idc.2021.03.005_bib166","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/fmb-2020-0217","article-title":"Rezafungin: a novel antifungal for the treatment of invasive candidiasis","volume":"16","author":"Ham","year":"2021","journal-title":"Future Microbiol"},{"issue":"8","key":"10.1016\/j.idc.2021.03.005_bib167","doi-asserted-by":"crossref","first-page":"e00161","DOI":"10.1128\/AAC.00161-17","article-title":"Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida Species","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2021.03.005_bib168","doi-asserted-by":"crossref","first-page":"e02136","DOI":"10.1128\/AAC.02136-19","article-title":"In\u00a0vitro activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST methodology and comparison with activity against C. albicans and C. glabrata and with the activities of six comparator agents","volume":"64","author":"Arendrup","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2021.03.005_bib169","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1128\/AAC.00234-15","article-title":"Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates","volume":"59","author":"Lamoth","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2021.03.005_bib171","doi-asserted-by":"crossref","first-page":"e02119","DOI":"10.1128\/AAC.02119-18","article-title":"SCY-078, a novel fungicidal agent, demonstrates distribution to tissues associated with fungal infections during mass balance studies with intravenous and oral [14C]SCY-078 in Albino and Pigmented Rats","volume":"63","author":"Wring","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2021.03.005_bib172","doi-asserted-by":"crossref","first-page":"e02268","DOI":"10.1128\/AAC.02268-19","article-title":"Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model","volume":"64","author":"Lee","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.idc.2021.03.005_bib173","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/jcph.1146","article-title":"Lack of Impact by SCY-078, a first-in-class oral fungicidal glucan synthase inhibitor, on the pharmacokinetics of rosiglitazone, a substrate for CYP450 2C8, supports the low risk for clinically relevant metabolic drug-drug interactions","volume":"58","author":"Wring","year":"2018","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.idc.2021.03.005_bib174","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1093\/jac\/dkz277","article-title":"MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis","volume":"74","author":"Spec","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2021.03.005_bib175","series-title":"Efficacy and safety of oral ibrexafungerp in 41 patients with refractory fungal diseases, interim analysis of a phase 3 open-label study (FURI).In: Proceedings of IDWeek2020.","author":"Alexander","year":"2020"},{"issue":"Supplement_3","key":"10.1016\/j.idc.2021.03.005_bib176","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.1093\/mmy\/myz012","article-title":"Antifungal drugs: what brings the future?","volume":"57","author":"Van Daele","year":"2019","journal-title":"Med Mycol"},{"issue":"45","key":"10.1016\/j.idc.2021.03.005_bib177","doi-asserted-by":"crossref","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"8","key":"10.1016\/j.idc.2021.03.005_bib178","doi-asserted-by":"crossref","first-page":"e00231","DOI":"10.1128\/AAC.00231-18","article-title":"Effect of the novel antifungal drug F901318 (Olorofim) on growth and viability of aspergillus fumigatus","volume":"62","author":"du Pr\u00e9","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2021.03.005_bib179","doi-asserted-by":"crossref","first-page":"e00487","DOI":"10.1128\/AAC.00487-18","article-title":"EUCAST determination of Olorofim (F901318) susceptibility of mold species, method validation, and MICs","volume":"62","author":"J\u00f8rgensen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2021.03.005_bib180","series-title":"Proceedings of the 27th European congress of clinical microbiology and infectious Diseases","article-title":"Assessment of the duration of infusion on the tolerability and repeat dose pharmacokinetics of F901318 in healthy volunteers","author":"Kennedy","year":"2017"},{"key":"10.1016\/j.idc.2021.03.005_bib181","series-title":"Proceedings of the 27th European congress of clinical microbiology and infectious Diseases","article-title":"An open-label study in healthy volunteers to evaluate the potential for cytochrome P450 3A4 inhibition by F901318 using oral midazolam as a probe","author":"Kennedy","year":"2017"},{"key":"10.1016\/j.idc.2021.03.005_bib182","series-title":"Proceedings of the 30th European Congress of clinical Microbiology & infectious diseases","article-title":"A\u00a0case of Lomentospora prolificans (LoPro) treated with the novel antifungal olorofim","author":"Chen","year":"2020"},{"key":"10.1016\/j.idc.2021.03.005_bib183","series-title":"Proceedings of the 30th European congress of clinical microbiology & infectious Diseases","article-title":"Olorofim for a case of severe disseminated Lomentospora prolificans infection","author":"Yen Tio","year":"2020"},{"key":"10.1016\/j.idc.2021.03.005_bib184","series-title":"Proceedings of the 30th European congress of clinical microbiology & infectious Diseases","article-title":"Successful use of the novel antifungal olorofim in the treatment of disseminated coccioidomycosis","author":"Harvey","year":"2020"},{"issue":"4","key":"10.1016\/j.idc.2021.03.005_bib185","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1046\/j.1365-2958.2003.03481.x","article-title":"Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly","volume":"48","author":"Tsukahara","year":"2003","journal-title":"Mol Microbiol"},{"issue":"5","key":"10.1016\/j.idc.2021.03.005_bib186","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jac\/dkz022","article-title":"Alastruey-Izquierdo A. In\u00a0vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies","volume":"74","author":"Rivero-Menendez","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.idc.2021.03.005_bib187","doi-asserted-by":"crossref","first-page":"e00425","DOI":"10.1128\/AAC.00425-18","article-title":"Significantly improved pharmacokinetics enhances in\u00a0vivo efficacy of APX001 against echinocandin- and multidrug-resistant candida isolates in a mouse model of invasive candidiasis","volume":"62","author":"Zhao","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2021.03.005_bib188","series-title":"Clinical safety and efficacy of novel antifungal, fosmanogepix, in the treatment of Candidemia: results from a phase 2 proof of concept trial. In: Proceedings of IDWeek 2020.","author":"Pappas","year":"2020"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552021000155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552021000155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:30:37Z","timestamp":1760196637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552021000155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":186,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0891552021000155"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2021.03.005","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antifungals in Clinical Use and the Pipeline","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2021.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}